Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
Abstract Vanishing bile duct syndrome (VBDS) is a serious drug induced liver injury characterized by chronic cholestasis and loss of intrahepatic bile ducts. VBDS has been reported also following checkpoint inhibitor treatment. We compared CD3 + , CD4 + , CD8 + , CD20 + , CD57 + , PD-1 + and PD-L1 +...
Saved in:
Main Authors: | Miro Saarela, Essi Parviainen, Ana Lleo, Luca di Tommaso, Hanna Raunio, Krista Kankaanranta, Katri Vuopala, Aino Rönkä, Sini Nurmenniemi, Raija Kallio, Arja Jukkola, Katri S. Selander |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Immunology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12865-025-00682-y |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
by: Chenyue Qian, et al.
Published: (2018-01-01) -
Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01) -
A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01) -
Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01) -
Bibliometric analysis of the research landscape of PD-1/PD-L1 inhibitors in the treatment of bowel cancer
by: Qingwei Luo, et al.
Published: (2025-02-01)